Skip to NavigationSkip to content

cardiovascular outcomes

Jardiance scores more cardiovascular outcomes data

Boehringer Ingelheim and Lilly co-market Jardiance for type 2 diabetes

A sub-group analysis of data from an outcomes study of Boehringer Ingelheim’s and Lilly’s Jardiance has found the diabetes drug reduces the risk of heart failure outcomes by 39%.

Earlier this year the two companies in the diabetes alliance presented preliminary data from the EMPA-REG OUTCOMES trial, which was the first to find that a blood sugar-lowering drug could reduce the risk of cardiovascular events.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches